Stanford Researchers Unveil Intranasal Universal Vaccine Offering Broad Protection Against Respiratory Threats in Mice

For decades, the pursuit of a universal vaccine—a single immunization capable of safeguarding against a vast array of infectious diseases—has remained a formidable, almost mythical, aspiration within the scientific community. This ambitious goal, long considered elusive, has now taken a significant stride towards reality, thanks to groundbreaking research from Stanford Medicine and its collaborators. In a new mouse study, scientists have successfully developed an experimental universal vaccine delivered intranasally, demonstrating wide-ranging protection in the lungs against a broad spectrum of respiratory viruses, bacteria, and even common allergens, with effects lasting for months.

The pioneering findings, detailed on February 19 in the prestigious journal Science, showcase the vaccine’s remarkable efficacy. Vaccinated mice exhibited robust protection against SARS-CoV-2 and other coronaviruses, virulent hospital-acquired bacteria like Staphylococcus aureus and Acinetobacter baumannii, and house dust mites, a prevalent allergen responsible for allergic asthma. Dr. Bali Pulendran, PhD, the Violetta L. Horton Professor II and professor of microbiology and immunology, and senior author of the study, expressed that the observed level of protection across such diverse respiratory threats significantly surpassed initial expectations. The lead author of this pivotal study is Dr. Haibo Zhang, PhD, a postdoctoral scholar in Dr. Pulendran’s laboratory. Should these promising results translate to human subjects, this single, easy-to-administer vaccine could revolutionize public health, potentially eliminating the need for multiple annual vaccinations against seasonal respiratory illnesses and providing rapid, broad-spectrum defense in the face of emerging pandemic threats.

The Enduring Challenge of Antigen Specificity in Vaccination

Since the late 18th century, when Edward Jenner famously introduced the concept of vaccination by using cowpox to confer immunity against smallpox, the fundamental strategy of vaccine development has largely revolved around antigen specificity. This classical approach involves presenting the immune system with a unique, recognizable fragment of a pathogen—such as the distinctive spike protein of SARS-CoV-2—to train the body to swiftly identify and neutralize the actual infectious agent upon subsequent exposure. Dr. Pulendran succinctly characterized this as "the paradigm of vaccinology for the last 230 years."

While highly effective for stable pathogens, this antigen-specific paradigm faces considerable challenges when confronted with rapidly evolving microbes. Many viruses, particularly respiratory ones like influenza and coronaviruses, possess an inherent ability to mutate their surface structures with alarming speed, a phenomenon known as antigenic drift and shift. These genetic alterations can render previously effective vaccines less potent or entirely obsolete, necessitating the frequent development and administration of updated formulations, as seen with annual flu shots and recurrent COVID-19 boosters. The constant race to update vaccines against these "shape-shifting" pathogens underscores a significant vulnerability in global health preparedness. Dr. Pulendran emphasized this point, stating, "It’s becoming increasingly clear that many pathogens are able to quickly mutate. Like the proverbial leopard that changes its spots, a virus can change the antigens on its surface."

Historically, efforts to create broader-acting vaccines have primarily focused on developing pan-variant immunizations targeting entire viral families—for instance, a single vaccine effective against all influenza strains or all coronaviruses. These endeavors typically aim to identify and target highly conserved viral components that mutate less frequently. However, the audacious concept of a single vaccine capable of defending against numerous unrelated pathogens has generally been dismissed as an unrealistic ambition. "We were interested in this idea because it sounded a bit outrageous," Dr. Pulendran admitted. "I think nobody was seriously entertaining that something like this could ever be possible." This context highlights the magnitude of the Stanford team’s breakthrough, challenging long-held assumptions in immunology.

A Paradigm Shift: Activating Integrated Immunity

The novel approach pioneered by the Stanford team diverges dramatically from traditional vaccine design. Instead of mimicking a specific viral or bacterial component, this experimental vaccine ingeniously imitates the complex communication signals that immune cells naturally exchange during an infection. By doing so, it orchestrates a powerful, synergistic response between the body’s two primary defense systems: the innate immune system and the adaptive immune system, resulting in a coordinated and remarkably durable protective effect.

Most existing vaccines predominantly stimulate the adaptive immune system. This sophisticated arm of immunity is responsible for generating highly specific antibodies and specialized T cells that precisely target particular pathogens. Crucially, adaptive immunity possesses immunological memory, allowing for a rapid and potent response upon re-exposure to the same pathogen, often conferring protection for years. In contrast, the innate immune system represents the body’s first line of defense. It responds almost instantaneously, within minutes of an infection, deploying a diverse arsenal of cells—including dendritic cells, neutrophils, and macrophages—to broadly attack perceived threats without prior exposure. However, a key characteristic of innate immunity is its transient nature; its heightened activity typically subsides within days.

Dr. Pulendran’s team recognized the inherent versatility and broad-spectrum capabilities of the innate system, which, despite its short-lived nature, can effectively combat a wide array of diverse microbes. This realization formed the bedrock of their innovative strategy. While innate immunity is typically ephemeral, intriguing hints have emerged suggesting that its effects can, under specific circumstances, persist for extended periods. A compelling example is the Bacillus Calmette-Guérin (BCG) vaccine, originally developed for tuberculosis and administered to approximately 100 million newborns annually worldwide. Numerous observational studies have indicated that the BCG vaccine may reduce infant mortality rates from infections other than tuberculosis, implying a form of extended, cross-protective immunity. However, the precise mechanisms underpinning this phenomenon, often referred to as "trained immunity," remained largely unclear, and results from different studies varied.

In 2023, Dr. Pulendran’s group made a pivotal discovery, elucidating how this cross-protection operates in mice. Their research revealed that the BCG vaccine not only triggered the expected adaptive immune responses but also elicited an unusual, sustained innate immune response that remained active for months. The breakthrough finding was that T cells, which are integral to the adaptive response and were recruited to the lungs, were actively sending signals that kept innate immune cells in an "activated" state. Dr. Pulendran explained, "Those T cells were providing a critical signal to keep the activation of the innate system, which typically lasts for a few days or a week, but in this case, it could last for three months." As long as this heightened innate activity persisted, the mice demonstrated robust protection against SARS-CoV-2 and other coronaviruses. The team meticulously identified these crucial T cell signals as specific cytokines that activate pathogen-sensing receptors known as toll-like receptors (TLRs) on innate immune cells. This foundational research paved the way for the current study, transforming a speculative hypothesis into a tangible reality. "In that paper, we speculated that since we now know how the tuberculosis vaccine is mediating its cross-protective effects, it would be possible to make a synthetic vaccine, perhaps a nasal spray, that has the right combination of toll-like receptor stimuli and some antigen to get the T cells into the lungs," Dr. Pulendran recounted. "Fast forward two and a half years and we’ve shown that exactly what we had speculated is feasible in mice."

The Mechanics of the Nasal Universal Vaccine

The new experimental formulation, currently designated GLA-3M-052-LS+OVA, is meticulously engineered to replicate the critical T cell signals that stimulate innate immune cells within the lungs. Beyond these signaling molecules, the vaccine incorporates a harmless antigen, ovalbumin (OVA), a common protein found in egg whites. The inclusion of OVA serves a crucial purpose: it effectively recruits T cells into the lungs, where they can then sustain the boosted innate immune response for an extended duration, ranging from weeks to several months.

In the study, mice received the vaccine via intranasal administration, delivered as small droplets into their noses. Some animal cohorts were given multiple doses, spaced one week apart, to assess the optimal regimen. Following vaccination, each mouse was intentionally exposed to a specific respiratory pathogen. The results were compelling: with three doses, the vaccinated mice maintained protection against SARS-CoV-2 and other coronaviruses for a minimum of three months. In stark contrast, unvaccinated control mice exhibited severe weight loss—a clear indicator of significant illness—and a substantial number succumbed to the infection. Their lungs showed extensive inflammation and harbored high viral loads. Conversely, vaccinated mice experienced minimal weight loss, all survived the viral challenge, and their lungs contained remarkably low levels of virus.

Dr. Pulendran characterized the vaccine’s impact as a "double whammy," highlighting its multi-layered defense mechanism. The sustained innate immune response played a critical role in dramatically reducing viral levels in the lungs, achieving an impressive 700-fold reduction. This powerful initial barrier significantly blunted the infection. Furthermore, any viruses that managed to circumvent this first line of defense were swiftly met by an extraordinarily rapid adaptive immune response. "The lung immune system is so ready and so alert that it can launch the typical adaptive responses—virus-specific T cells and antibodies—in as little as three days, which is an extraordinarily short length of time," Dr. Pulendran noted. "Normally, in an unvaccinated mouse, it takes two weeks." This accelerated adaptive response provides an additional, highly specific layer of protection, ensuring robust defense against the invading pathogen.

Broadening the Spectrum: Protection Against Bacteria and Allergens

Encouraged by the exceptional results against viral infections, the researchers expanded their investigation to test the vaccine’s efficacy against bacterial respiratory pathogens. They challenged vaccinated mice with Staphylococcus aureus and Acinetobacter baumannii, two common and often difficult-to-treat bacteria frequently implicated in hospital-acquired infections. Remarkably, the vaccinated mice were protected from these bacterial infections for approximately three months, mirroring the duration of protection observed against viruses. This finding further underscored the vaccine’s broad-spectrum capabilities.

The team then ventured into an entirely new territory for vaccination: allergens. "Then we thought, ‘What else could go in the lung?’" Dr. Pulendran recalled. "’Allergens.’" To explore this possibility, the researchers exposed mice to a protein derived from house dust mites, a ubiquitous allergen known to trigger allergic asthma. In unvaccinated mice, this exposure led to a strong Type 2 helper T cell (Th2) immune response, characterized by inflammation and the accumulation of mucus in their airways—hallmarks of an allergic reaction. In stark contrast, vaccinated mice exhibited a significantly weaker Th2 response and maintained clear airways, demonstrating the vaccine’s ability to mitigate allergic inflammation. This unprecedented finding suggests the potential for a single vaccine to address not only infectious diseases but also common allergic conditions affecting the respiratory system. "I think what we have is a universal vaccine against diverse respiratory threats," Dr. Pulendran concluded, summarizing the breadth of their achievement.

Future Horizons: From Bench to Bedside

The promising results from the mouse study pave the way for the critical next phase: human testing. The initial step will involve a Phase I safety trial, designed to assess the vaccine’s safety and tolerability in human volunteers. If these preliminary results are positive, larger-scale studies, including controlled exposure to infections, would follow to rigorously evaluate efficacy. Dr. Pulendran estimates that for human application, two doses delivered via a nasal spray could be sufficient to confer long-lasting protection.

With adequate funding and continued scientific progress, Dr. Pulendran optimistically believes that a universal respiratory vaccine could become available for public use within five to seven years. Such a breakthrough would have profound and transformative implications for global public health. It would significantly strengthen defenses against future pandemics, offering a readily deployable and broadly protective solution against novel threats. Furthermore, it would drastically simplify seasonal vaccination efforts, replacing the current regimen of multiple yearly shots with a single, convenient nasal spray.

"Imagine getting a nasal spray in the fall months that protects you from all respiratory viruses including COVID-19, influenza, respiratory syncytial virus, and the common cold, as well as bacterial pneumonia and early spring allergens," Dr. Pulendran envisioned. "That would transform medical practice." The potential benefits extend beyond convenience, encompassing reduced healthcare burdens, improved public health outcomes, and enhanced preparedness for unforeseen global health crises. The development of such a vaccine could also play a crucial role in promoting vaccine equity worldwide, simplifying logistics and distribution in resource-limited settings.

This groundbreaking research was a collaborative effort involving scientists from several esteemed institutions, including Emory University School of Medicine, the University of North Carolina at Chapel Hill, Utah State University, and the University of Arizona. Funding for this pivotal study was generously provided by the National Institutes of Health (grant AI167966), the Violetta L. Horton Professor endowment, the Soffer Fund endowment, and Open Philanthropy, underscoring the significant investment and belief in the potential of this revolutionary scientific endeavor.